Navigation Links
Caprion Biosciences Expands Biomarker Panel Portfolio to Include Predictive Tuberculosis (TB) Infections
Date:7/26/2017

MONTREAL, July 26th, 2017 /PRNewswire/ - Caprion Biosciences Inc., a world leading specialty CRO announced the publication of a novel study identifying host blood proteins predictive of early stage (latent) Mycobacterium tuberculosis (Mtb) infection using state-of-the-art ProteoCarta™, a mass spectrometry (MS) and multiple reaction monitoring (MRM-MS) platform.

Caprion Biosciences Inc. (CNW Group/Caprion Biosciences)
Caprion Biosciences Inc. (CNW Group/Caprion Biosciences)

The new data, recently published in EbioMedicine, expands and strengthens Caprion's existing portfolio of biomarkers assays for predicting and monitoring of active TB, supporting clients who are developing TB therapeutics and diagnostics. "These findings are very significant and could impact the way we approach treatment, providing a solid basis to accelerate the development of predictive testing" said Eustache Paramithiotis, Vice-President of Discovery at Caprion, who led the study in collaboration Charles Bark, MD and W. Henry Boom, MD from Case Western Reserve University.

In this proteomic study, host proteins expressed differentially between patients uninfected and individuals exposed to M. tuberculosis through contact with family members, which were followed over a period of 12 months. Caprion's bioinformatic analysis determined multiple biomarker signatures correlating with subsequent development of an immune response recognizing Mtb. These biomarker signatures may demonstrate individuals recently infected by Mtb at high risk for developing active tuberculosis (TB).  

About Latent M. Tuberculosis Infection (LTBI) and Active TB 
LTBI is a state of persistent immune response resulting from Mtb infection but without evidence of clinically active TB. Current immune-based tests for Mtb infection (LTBI) cannot distinguish recent from remote Mtb infection.  Individuals with recent Mtb infection are at highest risk for developing disease, i.e. TB.  These tests also cannot distinguish LTBI from TB. Worldwide, approximately one-third of the population is latently infected with Mtb, meaning that they do not display any symptoms, chest radiographic abnormalities, or other findings of active TB. Approximately 10% of people with LTBI will develop active TB and are the primary source of TB spreading. Their identification is critical to efforts aimed at controlling TB.

About Caprion Biosciences, Inc.   
Founded in 2000, Caprion is a leading specialty CRO laboratory providing an integrated platform in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion's immune monitoring division, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion's proteomics division, ProteoCarta™, offers proprietary gel-free, label-free MS for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Based in Montreal, Canada, and in Gosselies, Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 15 years. Caprion, a privately-held company, is majority owned by Global Healthcare Opportunities, or GHO Capital Partners LLP.

For more information, www.caprion.com


'/>"/>
SOURCE Caprion Biosciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Caprion Biosciences wird Kurzlehrgang und Poster bei Molecular Medicine Tri-Conference in San Francisco präsentieren
2. ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
3. ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
4. Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
5. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
6. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
7. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
8. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
9. TOMA Biosciences Releases the COMPASS Tumor Profiling System
10. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
11. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2019)... (PRWEB) , ... September 03, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... Director, Science & Technology will present at the upcoming Nordic Life Science ...
(Date:8/29/2019)... Kan. (PRWEB) , ... August 28, 2019 , ... ... expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the International Baking ... to solve today’s baking challenges from optimizing production efficiency to cost and waste ...
(Date:8/27/2019)... ... August 27, 2019 , ... Modality ... announce it has promoted Consulting Engineer, Robert Battista, to Senior Consulting engineer. , ... of onboarding and mentoring new engineers as well as the creation of additional ...
(Date:8/23/2019)... , ... August 22, 2019 , ... ... drug delivery modalities and is scheduled to broadcast 4Q/2019. Check your local listings ... state-of-the-art skin patches for generic drug delivery. Focusing on therapeutics for children and ...
Breaking Biology Technology:
(Date:9/8/2019)... ... September 06, 2019 , ... ... and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, ... cord (hUC) MSC paired cell and media system designed for product development. ...
(Date:8/29/2019)... ... August 29, 2019 , ... Advancements with Ted Danson announced ... upcoming episode, which is scheduled to broadcast 1Q/2020. Check local listings for more ... robotic surgical solutions for the treatment of patients suffering from spinal disorders. Traveling ...
(Date:8/27/2019)... FARMINGTON, Conn. (PRWEB) , ... August 26, 2019 , ... ... populations down to the strain level, has hired Bill McKenzie as its CEO and ... are expected to help Shoreline Biome meet growing demand for its products and expand ...
Breaking Biology News(10 mins):